Clinical Trials
Active Studies
PANTHER-IPF
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of N-acetylcysteine (with or without Prednisone and Azathioprine) in Idiopathic Pulmonary Fibrosis.
ASCEND
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Pirfenidone in Idiopathic Pulmonary Fibrosis.
1199.34 (enrollment currently held)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of BIBF1120 in Idiopathic Pulmonary Fibrosis.
RE-CAPACITY
An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF)
Currently Enrolling
Scleroderma Lung Study II
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of mycophenolate (CellCept) vs. cyclophosphamide(Cytoxan) in Scleroderma-associated Interstitial Lung Disease.
STX-003
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of STX-100 in Idiopathic Pulmonary Fibrosis.
Inhaled CO
A Phase II Trial of Inhaled Carbon Monoxide for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
UCSF Investigator-led Studies
RA-ILD
Understanding Rheumatoid Arthritis-Associated Interstitial Lung Disease. This is a two-center, prospective cohort study of patients with Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD). All participants will undergo serial collection (every 6 months) of clinical, radiologic, and physiologic data, as well as blood sample collection over 3 years. The goals of the study are to: 1) Measure change in pulmonary function and respiratory status; 2) Measure molecular profiles of RA autoantibodies; and 3) Analyze DNA for telomere length. Subjects will be paid for their participation.
For more information, please contact Archer Eller, Clinical Trial Manager, at archer.eller@ucsf.edu or 415-502-1958.
Microaspiration in IPF
UCSF is studying the role of microaspiration in patients with idiopathic pulmonary fibrosis (IPF). This study aims to diagnose microaspiration and identify conditions associated with its presence and severity. Patients with a biopsy-proven diagnosis of IPF will be considered for this study. Participation involves at least one visit to UCSF. Subjects will be paid for their participation.
For more information, please contact Archer Eller, Clinical Trial Manager, at archer.eller@ucsf.edu or 415-502-1958
UCSF Sarcoidosis Clinical Research
The UCSF ILD Program is studying sarcoidosis through clinical research studies. Ongoing studies include investigating how a newly discovered T-cell may contribute to the development of sarcoidosis and describing the complex symptom of fatigue in patients with sarcoidosis. Study visits include health history questionnaires and a blood draw. Individuals who have not had a recent pulmonary function test will be given the opportunity to have one. Subjects will be reimbursed, and parking can be validated.
If interested, please call the sarcoidosis recruitment hotline at 415-476-5896. More information can be found at http://sarcoidosis.ucsf.edu/
Interstitial Lung Disease Registry
The Interstitial Lung Disease Registry is an ongoing clinical database of patients that allows researchers to better define the characteristics of these diseases, their potential causes, and their natural history.
Interstitial Lung Disease Blood and Tissue Repository
The Interstitial Lung Disease Blood and Tissue Repository is a collection of serum, plasma, lung fluid, and lung tissue that is tightly linked to the Interstitial Lung Disease Registry. These samples allow researchers to investigate biological mechanisms of disease and link their findings to clinically important measures like symptom severity and disease progression.